Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial

Simple item page
dc.conference.dateMAY 05-08, 2021
dc.conference.titleESMO Breast Cancer Virtual Congress
dc.contributor.authorDang, C.
dc.contributor.authorEwer, M. S.
dc.contributor.authorDelaloge, S.
dc.contributor.authorFerrero, J-M.
dc.contributor.authorColomer, R.
dc.contributor.authorde la Cruz Merino, L.
dc.contributor.authorDadswell, K.
dc.contributor.authorVerrill, M.
dc.contributor.authorEiger, D.
dc.contributor.authorSarkar, S.
dc.contributor.authorde Haas, S.
dc.contributor.authorRestuccia, E.
dc.contributor.authorSwain, S. M.
dc.contributor.authoraffiliation[Dang, C.] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Med Serv, 1275 York Ave, New York, NY 10021 USA
dc.contributor.authoraffiliation[Ewer, M. S.] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA
dc.contributor.authoraffiliation[Delaloge, S.] Inst Gustave Roussy, Dept Med Oncol, Paris, France
dc.contributor.authoraffiliation[Ferrero, J-M.] Ctr Antoine Lacassagne, Dept Med Oncol, Nice, France
dc.contributor.authoraffiliation[Colomer, R.] Hosp Univ La Princesa, Div Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[de la Cruz Merino, L.] Hosp Univ Virgen Macarena, Dept Clin Oncol, Seville, Spain
dc.contributor.authoraffiliation[Dadswell, K.] Roche Prod Ltd, Global Prod Dev, Welwyn Garden City, Herts, England
dc.contributor.authoraffiliation[Verrill, M.] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England
dc.contributor.authoraffiliation[Eiger, D.] F Hoffmann La Roche & Cie AG, Prod Dev Oncol, Basel, Switzerland
dc.contributor.authoraffiliation[Sarkar, S.] Roche Prod Ltd, Welwyn Garden City, Herts, England
dc.contributor.authoraffiliation[de Haas, S.] F Hoffmann La Roche AG Switzerland, Oncol Biomarker Dev, Basel, Switzerland
dc.contributor.authoraffiliation[Restuccia, E.] F Hoffmann La Roche Ltd, Global Prod Dev, Med Affairs Oncol, Basel, Switzerland
dc.contributor.authoraffiliation[Swain, S. M.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA
dc.contributor.funderF. Hoffmann-La Roche Ltd.
dc.date.accessioned2025-01-07T16:06:09Z
dc.date.available2025-01-07T16:06:09Z
dc.date.issued2021-05-08
dc.identifier.doi10.1016/j.annonc.2021.03.057
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753421009352/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27618
dc.identifier.wosID648924400044
dc.issue.number2
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.page.numberS38-S39
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titlePertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía